2. Metabolic Enzyme/Protease Immunology/Inflammation
  3. MMP IFNAR
  4. MEDI-3622

MEDI-3622 is a human monoclonal antibody against ADAM17. MEDI-3622 blocks the ADAM17-mediated shedding of CD16A and CD62L on NK cells, and binds with high specificity to a surface loop unique to the metalloprotease catalytic domain of ADAM17. MEDI-3622 enhances IFNγ production by NK cells when they bind to antibody-coated tumor cells. MEDI-3622 can be used in the research of ovarian cancer, Burkitt lymphoma, head and neck cancer, and colorectal cancer.

For research use only. We do not sell to patients.

MEDI-3622

MEDI-3622 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

MEDI-3622 Related Antibodies

Top Publications Citing Use of Products

View All MMP Isoform Specific Products:

View All Isoforms
MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

MEDI-3622 is a human monoclonal antibody against ADAM17. MEDI-3622 blocks the ADAM17-mediated shedding of CD16A and CD62L on NK cells, and binds with high specificity to a surface loop unique to the metalloprotease catalytic domain of ADAM17. MEDI-3622 enhances IFNγ production by NK cells when they bind to antibody-coated tumor cells. MEDI-3622 can be used in the research of ovarian cancer, Burkitt lymphoma, head and neck cancer, and colorectal cancer[1].

Species Reactivity

Human
IC50 & Target[1]

ADAM17

 

In Vitro

MEDI-3622 specifically recognizes ADAM17 on human peripheral blood leukocytes, including both CD56bright CD3− and CD56dim CD3− human NK cell subsets[1].
MEDI-3622 (1 µg/mL; 2 h) blocks ADAM17-mediated shedding of CD16A and CD62L by enriched human peripheral blood NK cells activated by trastuzumab-bound SKOV-3 ovarian cancer cells, without inhibiting NK cell activation (CD107a upregulation)[1].
MEDI-3622 (1 µg/mL; 4 h) significantly enhances IFNγ secretion by enriched human peripheral blood NK cells stimulated by trastuzumab-bound SKOV-3 or MA-148 ovarian cancer cells, and rituximab-bound Raji Burkitt's lymphoma cells, across all tested effector:target ratios (10:1 to 1:10), but does not affect granzyme A or granzyme B secretion[1].
MEDI-3622 (1 µg/mL; 4 h) enhancement of IFNγ secretion by enriched human peripheral blood NK cells stimulated with trastuzumab-bound SKOV-3 ovarian cancer cells is dependent on CD16A activity[1].
MEDI-3622 (1 µg/mL; 4 h) enhances IFNγ secretion by NK92 human NK cells expressing wildtype CD16A (but not non-cleavable CD16A) stimulated by trastuzumab-bound SKOV-3 ovarian cancer cells, indicating the effect is mediated by blocking CD16A shedding[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MEDI-3622 Related Antibodies

ELISA Assay[1]

Cell Line: recombinant CD16A-expressing NK92 human NK cell line (wildtype CD16A and non-cleavable CD16A variants)
Concentration: 1 µg/mL
Incubation Time: 4 h
Result: Significantly enhanced IFNγ secretion by NK92 cells expressing wildtype CD16A exposed to trastuzumab-bound SKOV-3 cells.
Had no effect on IFNγ secretion by NK92 cells expressing non-cleavable CD16A (ncCD16A) exposed to trastuzumab-bound SKOV-3 cells.
NK92 cells expressing ncCD16A secreted significantly higher levels of IFNγ than NK92 cells expressing wildtype CD16A when exposed to trastuzumab-bound SKOV-3 cells, even without MEDI-3622 treatment.
Gene ID

6868  [NCBI]

Accession
Target

ADAM17/TACE
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

MEDI-3622 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MEDI-3622MEDI3622MEDI 3622MMPIFNARMatrix metalloproteinasesInterferon-α/β receptorInterferon-alpha/beta receptormouse xenograft modelsNK cellsmouse leukocytesIFNγADAM17human colorectal tumor cellshuman head and neck tumor cellsCD16ACD62Lhuman leukocytesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
MEDI-3622
Cat. No.:
HY-P992406
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.